07.12.11
New in vitro and in vivo studies of Biothera’s beta-glucans published in the journal Blood demonstrate the importance of molecular structure in designing effective immunotherapies.
The paper confirms research published in the April issue of Nature that found differences in yeast-derived beta-glucan structures determine their ability to bind to receptors on innate immune cells and the specific immune responses that result.
Biothera’s soluble and particulate beta-glucans depend on different receptors to elicit their biological activities. The Dectin-1 pathway is essential for Biothera’s particulate beta-glucan to mediate immune modulatory effects on dendritic cell activation, macrophage phagocytosis and CD4 (TH1) and CD8 (Cytotoxic) T-lymphocyte activation. In contrast, Biothera’s soluble beta-glucan is dependent on Complement Receptor binding to elicit neutrophil-mediated responses to antibody targeted cells and does not directly effect T cell activation. For further information: www.biothera.com
The paper confirms research published in the April issue of Nature that found differences in yeast-derived beta-glucan structures determine their ability to bind to receptors on innate immune cells and the specific immune responses that result.
Biothera’s soluble and particulate beta-glucans depend on different receptors to elicit their biological activities. The Dectin-1 pathway is essential for Biothera’s particulate beta-glucan to mediate immune modulatory effects on dendritic cell activation, macrophage phagocytosis and CD4 (TH1) and CD8 (Cytotoxic) T-lymphocyte activation. In contrast, Biothera’s soluble beta-glucan is dependent on Complement Receptor binding to elicit neutrophil-mediated responses to antibody targeted cells and does not directly effect T cell activation. For further information: www.biothera.com